Poxel Releases Positive Preclinical Results for HCM Treatment

Poxel SA has announced promising preclinical results for its drug candidate PXL065 in hypertrophic cardiomyopathy (HCM). Conducted at the TUM University Hospital German Heart Center with funding from the German Center for Cardiovascular Research, the study demonstrated significant benefits of PXL065 in a mouse model, reducing myocardial hypertrophy and cardiac fibrosis.

PXL065, a deuterium-stabilized R-stereoisomer of pioglitazone, targets mitochondrial dysfunction, inflammation, and fibrosis. These results support its development as a potential treatment for both symptomatic and asymptomatic HCM.

CEO Thomas Kuhn emphasized the high medical need for new treatments for HCM, a progressive genetic cardiac disorder. The successful preclinical results pave the way for further clinical development.

The full results are slated for presentation at an upcoming scientific meeting, and Poxel plans to identify the optimal patient population for treatment with PXL065, pending additional funding.